Ocular Therapeutix (NASDAQ:OCUL) Insider Pravin Dugel Sells 124,882 Shares

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Pravin Dugel sold 124,882 shares of Ocular Therapeutix stock in a transaction dated Thursday, February 12th. The stock was sold at an average price of $9.04, for a total value of $1,128,933.28. Following the sale, the insider directly owned 3,033,078 shares of the company’s stock, valued at $27,419,025.12. This trade represents a 3.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Ocular Therapeutix Stock Down 21.3%

Shares of NASDAQ OCUL traded down $1.89 during midday trading on Tuesday, hitting $6.99. 51,503,167 shares of the company’s stock were exchanged, compared to its average volume of 4,346,415. The firm’s fifty day simple moving average is $11.22 and its 200-day simple moving average is $11.78. The company has a market cap of $1.52 billion, a PE ratio of -4.85 and a beta of 0.90. Ocular Therapeutix, Inc. has a twelve month low of $5.78 and a twelve month high of $16.44. The company has a debt-to-equity ratio of 0.11, a current ratio of 15.39 and a quick ratio of 15.32.

Ocular Therapeutix (NASDAQ:OCUL) last announced its earnings results on Thursday, February 5th. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.04. The firm had revenue of $13.25 million during the quarter, compared to analysts’ expectations of $16.13 million. Ocular Therapeutix had a negative return on equity of 70.68% and a negative net margin of 511.90%.The business’s revenue was down 22.4% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.29) EPS. Research analysts predict that Ocular Therapeutix, Inc. will post -0.98 EPS for the current fiscal year.

Hedge Funds Weigh In On Ocular Therapeutix

Several institutional investors and hedge funds have recently modified their holdings of OCUL. Logos Global Management LP grew its stake in Ocular Therapeutix by 7.7% in the 4th quarter. Logos Global Management LP now owns 3,500,000 shares of the biopharmaceutical company’s stock worth $42,490,000 after acquiring an additional 250,000 shares during the period. Schonfeld Strategic Advisors LLC purchased a new position in Ocular Therapeutix during the fourth quarter worth about $150,000. AQR Capital Management LLC grew its holdings in Ocular Therapeutix by 23.9% in the 4th quarter. AQR Capital Management LLC now owns 180,723 shares of the biopharmaceutical company’s stock valued at $2,194,000 after buying an additional 34,847 shares during the period. Cetera Investment Advisers boosted its holdings in Ocular Therapeutix by 1.2% in the fourth quarter. Cetera Investment Advisers now owns 722,540 shares of the biopharmaceutical company’s stock valued at $8,772,000 after acquiring an additional 8,474 shares during the last quarter. Finally, Jain Global LLC grew its holdings in shares of Ocular Therapeutix by 57.7% during the 4th quarter. Jain Global LLC now owns 25,116 shares of the biopharmaceutical company’s stock worth $305,000 after purchasing an additional 9,191 shares during the period. Hedge funds and other institutional investors own 59.21% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Royal Bank Of Canada reiterated an “outperform” rating and issued a $30.00 price objective on shares of Ocular Therapeutix in a research report on Thursday, February 5th. Jefferies Financial Group reiterated a “buy” rating on shares of Ocular Therapeutix in a report on Tuesday. Needham & Company LLC reaffirmed a “buy” rating and issued a $20.00 target price on shares of Ocular Therapeutix in a report on Monday, December 8th. HC Wainwright lifted their price target on shares of Ocular Therapeutix from $19.00 to $21.00 and gave the company a “buy” rating in a research report on Monday, December 8th. Finally, Wall Street Zen raised Ocular Therapeutix from a “sell” rating to a “hold” rating in a research note on Saturday, February 7th. Twelve investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $24.00.

Ocular Therapeutix News Summary

Here are the key news stories impacting Ocular Therapeutix this week:

• Positive Sentiment: SOL‑1 demonstrated statistical superiority to Regeneron’s Eylea on the trial’s vision endpoint, supporting Ocular’s plan to pursue an FDA filing and a potential new treatment option in wet AMD. Ocular Therapeutix’s eye drug superior to Regeneron’s Eylea in late-stage trial
• Positive Sentiment: Company and coverage note a clear regulatory path — Ocular is talking about an FDA submission based on the Phase 3 win, which could materially change the company’s product mix if approved. Ocular’s Hydrogel Beats Regeneron’s Eylea in Wet AMD Study, Plots Path to FDA
• Neutral Sentiment: Ocular released topline SOL‑1 results and corporate commentary; the data readout itself is positive but investors are parsing subgroup/endpoint details and next steps. Ocular Therapeutix releases positive topline results from SOL-1
• Negative Sentiment: Despite the win, shares fell sharply because the observed benefit was characterized as modest and, crucially, the comparator in some analyses was a lower‑dose/less‑favorable version of Eylea — raising questions about clinical meaningfulness and commercial differentiation. Ocular Therapeutix plunges as modest benefit overshadow trial win over Regeneron’s Eylea
• Negative Sentiment: Market and analyst coverage flagged investor skepticism — headlines note a 25–35% intraday decline on heavy volume as traders focused on practical uptake, labeling the result “positive but underwhelming.” Ocular claims a win with eye drug data even as shares sink
• Negative Sentiment: Commentary points to potential regulatory and commercial hurdles (e.g., demonstrating meaningful advantage vs standard‑dose Eylea, pricing/reimbursement, and adoption), which could delay or limit upside even if FDA accepts a filing. Ocular Therapeutix eyes FDA filing with ph. 3 wet AMD win over Regeneron’s leading Eylea

Ocular Therapeutix Company Profile

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.